RENACER

RENACER

Related projects

Publications

A clinically-compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

Zhu L, et al. EMBO Molecular Medicine. (2022).

Link to publication

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

Monteiro C, Miarka L, et al. Nature Medicine (2022).

Link to publication

Protocol to generate murine organotypic brain cultures for drug screening and evaluation of anti-metastatic efficacy

Lucía Zhu, Lauritz Miarka, Patricia Baena, María Perea-García, Manuel Valiente. STAR Protocols (2023)

Link to publication

Emerging targets for cancer treatment: S100A9/RAGE

M. Valiente, J.M. Sepúlveda, A. Pérez. ESMO Open (2023)

Link to publication

Updating cancer research with patient-focused networks

M. Valiente & Eva Ortega-Paíno. Trends in Cancer (2023)

Link to publication

TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis acting on infiltrating CD8+ T cells.

Cancer Discovery (2024)

First author/s: Priego N et al.
Corresponding author/s: Valiente M

Updating cancer research with patient-focused networks

Trends in Cancer (2023)

First author/s: Valiente M, Ortega-Paino E
Corresponding author/s: Valiente M

Protocol to generate murine organotypic brain cultures for drug screening and evaluation of anti-metastatic efficacy

STAR Protocols (2023)

First author/s: Zhu L et al.
Corresponding author/s: Valiente M

Emerging targets for cancer treatment: S100A9/RAGE

ESMO Open (2023)

First author/s: Valiente M
Corresponding author/s: Valiente M, Sepúlveda JM, Pérez A

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Nature Medicine (2022)

First author/s: Monteiro C, Miarka L et al.
Corresponding author/s: Valiente M

A clinically-compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

EMBO Molecular Medicine (2022)

First author/s: Zhu L et al.
Corresponding author/s: Valiente M

We have expanded our initial collaboration with a single hospital to 12 nation-wide health care institutions. This network is called RENACER (Red Nacional de Metastasis Cerebral). We work in a coordinated manner to identify, collect, biobank and validate new candidates, drugs and biomarkers in human brain metastasis.

We have established a network that allow us to obtain fresh human brain metastases from neurosurgeries. This effort has been possible in collaboration with the CNIO Biobank and the following hospitals: Hospital 12 de Octubre, Hospital de La Princesa, Hospital Vall d’Hebron, Complejo Hospitalario de Navarra, Hospital Universitario de Burgos, Hospital de Bellvitge, Hospital Universitario de Toledo, Hospital Virgen del Rocío, Hospital Rio Ortega de Valladolid, CHUVI, Hospital Universitario de Albacete, Hospital de La Paz. Collected human brain metastases are analyzed molecularly and tested by their sensitivity to selected drugs using METPlatform.

We have been able to create a long-term and dynamic network that vertebrate the optimal strategy to collect, process and analyze brain metastasis under the experience of the CNIO Biobank.

RENACER has become a national and international reference for researchers and clinicians interested in brain metastasis and a repository for this valuable material. We are also committed to make findings and resources generated by the network useful to promote clinical trials and research on brain metastasis in a continuous effort to benefit patients.

RENACER

Related projects

Publications

TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis acting on infiltrating CD8+ T cells.

Cancer Discovery (2024)

First author/s: Priego N et al.
Corresponding author/s: Valiente M

Updating cancer research with patient-focused networks

Trends in Cancer (2023)

First author/s: Valiente M, Ortega-Paino E
Corresponding author/s: Valiente M

Protocol to generate murine organotypic brain cultures for drug screening and evaluation of anti-metastatic efficacy

STAR Protocols (2023)

First author/s: Zhu L et al.
Corresponding author/s: Valiente M

Emerging targets for cancer treatment: S100A9/RAGE

ESMO Open (2023)

First author/s: Valiente M
Corresponding author/s: Valiente M, Sepúlveda JM, Pérez A

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Nature Medicine (2022)

First author/s: Monteiro C, Miarka L et al.
Corresponding author/s: Valiente M

A clinically-compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

EMBO Molecular Medicine (2022)

First author/s: Zhu L et al.
Corresponding author/s: Valiente M

More information

Valiente Lab
CNIO - Centro Nacional de Investigaciones Oncológicas C/ Melchor Fernández Almagro, 3 · E-28029 Madrid

© Valiente Lab 2025

RENACER

Related projects

Publications

TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis acting on infiltrating CD8+ T cells.

Cancer Discovery (2024)

First author/s: Priego N et al. Corresponding author/s: Valiente M

Updating cancer research with patient-focused networks

Trends in Cancer (2023)

First author/s: Valiente M, Ortega-Paino E Corresponding author/s: Valiente M

Protocol to generate murine organotypic brain cultures for drug screening and evaluation of anti-metastatic efficacy

STAR Protocols (2023)

First author/s: Zhu L et al. Corresponding author/s: Valiente M

Emerging targets for cancer treatment: S100A9/RAGE

ESMO Open (2023)

First author/s: Valiente M Corresponding author/s: Valiente M, Sepúlveda JM, Pérez A

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Nature Medicine (2022)

First author/s: Monteiro C, Miarka L et al. Corresponding author/s: Valiente M

A clinically-compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

EMBO Molecular Medicine (2022)

First author/s: Zhu L et al. Corresponding author/s: Valiente M

More information

Valiente Lab CNIO - Centro Nacional de Investigaciones Oncológicas C/ Melchor Fernández Almagro, 3 · E-28029 Madrid

© Valiente Lab 2025

First author/s: Priego N et al.
Corresponding author/s: Valiente M

First author/s: Valiente M, Ortega-Paino E
Corresponding author/s: Valiente M

First author/s: Zhu L et al.
Corresponding author/s: Valiente M

First author/s: Valiente M
Corresponding author/s: Valiente M, Sepúlveda JM, Pérez A

First author/s: Monteiro C, Miarka L et al.
Corresponding author/s: Valiente M

First author/s: Zhu L et al.
Corresponding author/s: Valiente M

Valiente Lab
CNIO - Centro Nacional de Investigaciones Oncológicas C/ Melchor Fernández Almagro, 3 · E-28029 Madrid